213201-98-0

Basic information

• Product Name: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE
• Synonyms: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE;2,4-dichloro-6-(piperidin-1-yl)pyriMidine;2,4-Dichloro-6-(1-piperidinyl)pyrimidine
• CAS NO: 213201-98-0
• Molecular Formula: C₉H₁₁Cl₂N₃
• Molecular Weight: 232.11
• Mol File: 213201-98-0.mol

Chemical Properties

• Boiling Point: 372.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.349
• PKA: 0.59±0.39(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(213201-98-0)
• EPA Substance Registry System: 2,4-DICHLORO-6-PIPERIDINYLPYRIMIDINE(213201-98-0)

Safety Data

• Hazardous Substances Data: 213201-98-0(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
2,4-Dichloro-6-piperidinylpyrimidine is used as a herbicidal agent for controlling a broad spectrum of broadleaf weeds in various crops, lawns, and other vegetation. Its effectiveness in inhibiting the enzyme acetohydroxyacid synthase makes it a valuable tool in ensuring the healthy growth of desired plants by eliminating competing weeds.
This herbicide plays a significant role in enhancing crop yields and maintaining the aesthetic appeal of lawns and other green spaces by providing an efficient and targeted method of weed control.

Upstream product

• 110-89-4 piperidine 
• 3764-01-0 2,4,6-trichloropyrimidine 

Downstream Products

• 1350641-32-5 C₂₂H₂₃ClFN₅O 
• 1350641-31-4 N₄-(3-fluoro-2-methylphenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrimidine-2,4-diamine 
• 1350641-30-3 C₂₃H₂₆FN₅O 
• 1350641-29-0 C₂₄H₂₆F₃N₅O 
• 1350641-28-9 N₄-(3-fluoro-4-methoxyphenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrimidine-2,4-diamine 
• 1350641-27-8 C₂₃H₂₅F₂N₅O₂ 
• 1350641-26-7 N₄-(3-(difluoromethoxy)phenyl)-N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)pyrim-idine-2,4-diamine 
• 1350641-25-6 C₂₃H₂₄F₃N₅O 
• 1350641-24-5 N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)-N₄-(4-(trifluoromethoxy)phene-yl)pyrimidine-2,4-diamine 
• 1350641-23-4 N₂-(4-methoxyphenyl)-6-(piperidin-1-yl)-N₄-(3-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
• 1350641-22-3 C₂₄H₂₉N₅O 
• 1350641-21-2 C₂₄H₂₉N₅O 
• 1350641-20-1 C₂₇H₃₁F₄N₇ 
• 1350641-19-8 C₂₇H₃₁F₄N₇O 

Relevant articles and documents

Novel antiallergic agents. Part I: Synthesis and pharmacology of pyrimidine amide derivatives

We have synthesized many pyrimidine amide derivatives. Novel pyrimidine bis-glycolic amide derivatives showed moderate inhibition in the rat passive cutaneous anaphylaxis (PCA) assay by oral administration. Among these compounds, 2,4-bis(methoxyacetylamino)-6-piperidinopyrirnidine (2i) exhibited significant inhibition. However the compound (2i) did not inhibit antigen-induced histamine or SRS-A release from lung fragments of the guinea-pig at less than 10-4 M. Derivatives of 2i have also notable or moderate activity in the rat PCA assay. Compound 2h which has no oxygen atom at the α-position of the amide carbonyl group and, compound 17 which has no amide carbonyl group, showed no inhibition in the rat PCA assay. We supposed that both the amide carbonyl group and the oxygen atom at α-position of the amide carbonyl group play an important role in inhibiting the rat PCA reaction. These pyrimidine bis-glycolic amide derivatives have a novel structure and unique activity which suggests they may be potentially useful in the treatment of allergic diseases. Copyright (C) 1998 Elsevier Science Ltd.

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2

GalR1 and GalR2 represent unique pharmacological targets for treatment of seizures and epilepsy. A novel series of 2,4,6-triaminopyrimidine derivatives were synthesized and found to have sub-micromolar affinity for GalR2. Optimization of a series of 2,4,6